In the multicentre Turkish League Against Rheumatism (TLAR) network study, 1,134 patients (726 females, 408 males) diagnosed with PsA according to the CASPAR criteria were included. Disease activity was evaluated using different scores (e.g. disease activity score 28 [DAS28], disease activity index for psoriatic arthritis [DAPSA], minimal disease activity [MDA]). In addition, psychiatric comorbidity and quality of life were assessed by the health assessment questionnaire (HAQ), the Hospital Anxiety and Depression Scale (HAD), the fatigue visual analogue score (VAS from 0-10), and the fibromyalgia rapid screening tool. Disease activity as well as remission were compared between men and women, and the association with psychiatric symptoms, fatigue, and fibromyalgia was assessed in both sexes.
Women with PsA showed higher disease activity and lower rates of remission compared with men (P<0.05). In addition, women had significantly higher anxiety, depression, and fibromyalgia scores than men (P<0.05). On the other hand, significantly more men achieved MDA compared to women (P<0.05). Men and women who achieved MDA all had significant improvements in the scores of fatigue, fibromyalgia, anxiety, and depression, as well as in their quality of life. The frequencies of dactylitis, enthesitis, inflammatory bowel disease, and arthritis were similar in men and women, while men had a higher incidence of spondylitis (P<0.05).
- Duruöz MT, et al. Abstract 2443. ACR 2019. November 8-13, Atlanta (GA/USA).
Posted on
Previous Article
« Calcium pyrophosphate deposition disease: an independent risk factor for cardiovascular complications Next Article
Filgotinib promising in RA patients naïve to methotrexate »
« Calcium pyrophosphate deposition disease: an independent risk factor for cardiovascular complications Next Article
Filgotinib promising in RA patients naïve to methotrexate »
Table of Contents: ACR 2019
Featured articles
Late-Breaking Abstracts
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Calcium pyrophosphate deposition disease: an independent risk factor for cardiovascular complications
Proteome abnormalities improve prediction of RA development
RA patients in remission benefit from continued therapy with conventional DMARDs
Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis
Corticosteroid therapy in GCA: higher platelets – lower relapse rate
Spotlight on Rheumatoid Arthritis
Filgotinib promising in RA patients naïve to methotrexate
Sustained efficacy of monotherapy with upadacitinib after 48 weeks
Biologics show similar activity in patients with elderly-onset RA
Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration
Treatment decisions should not be guided by ultrasound findings
Cancer treatment with checkpoint inhibitors in RA patients?
What is Hot in Systemic Lupus Erythematosus
Anifrolumab succeeds in second phase 3 trial in SLE
Depression closely related to fatigue in SLE patients
Spondyloarthritis – The Beat Goes On
Psoriasis onset determines sequence of symptoms
Higher psychiatric comorbidity in women with PsA
JAK1 inhibition shows remarkable efficacy in AS
CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients
Osteoarthritis – State-of-the-Art
Hand OA: low-dose corticosteroids improve symptoms
Opioids: no quality of life benefits for OA patients
Walking speed is a predictor of mortality in patients with knee OA
Reproductive Issues in Rheumatic Disease
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
Prevention of congenital heart block may be possible with hydroxychloroquine
TNFi for RA during pregnancy – to stop or not to stop?
Vasculitis – Novel Treatment Modalities
Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis
Prolonged remission after stop of tocilizumab for patients with giant cell arteritis
Best of the Posters
Antifibrotic therapy slows disease progression independent of corticosteroid use
Fibromyalgia patients often experienced abuse in childhood
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com